• Medientyp: Sonstige Veröffentlichung; E-Artikel
  • Titel: Novel bisquaternary oximes - Reactivation of acetylcholinesterase and butyrylcholinesterase inhibited by paraoxon
  • Beteiligte: Kuca, Kamil [VerfasserIn]; Musilova, Lucie [VerfasserIn]; Paleček, Jiri [VerfasserIn]; Cirkva, Vladimir [VerfasserIn]; Paar, Martin [VerfasserIn]; Musilek, Kamil [VerfasserIn]; Hrabinova, Martina [VerfasserIn]; Pohanka, Miroslav [VerfasserIn]; Karasova, Jana Zdarova [VerfasserIn]; Jun, Daniel [VerfasserIn]
  • Erschienen: Basel : MDPI AG, 2009
  • Erschienen in: Molecules 14 (2009), Nr. 12
  • Ausgabe: published Version
  • Sprache: Englisch
  • DOI: https://doi.org/10.15488/1498; https://doi.org/10.3390/molecules14124915
  • ISSN: 1420-3049
  • Schlagwörter: drug effect ; cholinesterase ; paraoxon ; article ; metabolism ; Butyrylcholinesterase ; Oximes ; nuclear magnetic resonance spectroscopy ; Nerve agent ; chemistry ; Magnetic Resonance Spectroscopy ; Reactivator ; Pesticide ; Acetylcholinesterase ; enzyme activator ; Enzyme Reactivators ; Oxime ; Scavenger
  • Entstehung:
  • Anmerkungen: Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.
  • Beschreibung: Four novel bisquaternary aldoxime cholinesterase reactivators differing in their chemical structure were prepared. Afterwards, their biological activity was evaluated for their ability to reactivate acetylcholinesterase (AchE; EC 3.1.1.7) and butyryl-cholinesterase (BuChE; EC 3.1.1.8) inhibited by paraoxon. Their reactivation activity was compared with standard reactivators - pralidoxime, obidoxime and HI-6 - which are clinically used at present. As it resulted, none of the prepared compounds surpassed obidoxime, which is considered to be the most potent compound if used for reactivation of AChE inhibited by paraoxon. In case of BuChE reactivation, two compounds (K053 and K068) achieved similar results as obidoxime. ; Ministry of Defence/FVZ0000604
  • Zugangsstatus: Freier Zugang
  • Rechte-/Nutzungshinweise: Namensnennung - Nicht-kommerziell - Weitergabe unter gleichen Bedingungen (CC BY-NC-SA)